Drugs / DTwP-HepB-Sabin IPV-Hib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04073459 | Nov 2019 → Apr 2020 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +2 | LG Chem | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTwP-HepB-Sabin IPV-Hib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04073459 ↗ |
| Known as | LBVD | “LBVD (Fully Liquid Hexavalent Vaccine; Adsorbed Diphtheria-Tetanus-Pertussis-Hepatitis B- Inactivated Poliomyelitis (Sabin) and Haemophilus Influenzae Type b Conjugate Vaccine)” NCT04073459 ↗ |
| Modality | Vaccine | “candidate hexavalent vaccine” NCT04073459 ↗ |
| Route | Intramuscular | “Intramuscular injection into the anterolateral area of the thigh” NCT04073459 ↗ |